AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's...

Related Keywords

France ,Laurent Peyrin Biroulet ,Roopal Thakkar ,Facebook ,European Medicines Agency ,Instagram ,Crohn Colitis Foundation Of America ,Abbvie Inc ,University Hospital Of Nancy ,Drug Administration ,Exchange Commission ,Youtube ,Linkedin ,Boehringer Ingelheim ,Twitter ,Infinity Institute ,Abbvie Ltd ,Disease Activity Index ,United European Gastroenterology ,Ahead Study ,University Hospital ,Important Safety Information ,Medication Guide ,Consumer Brief Summary ,Pregnancy Registry ,Full Prescribing Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Inflammatory Bowel ,Colitis Foundation ,Accessed March ,Abbvie ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,